J&J pays $500M in cash to grab rights to a new star can­cer drug at ar­genx

J&J ex­ecs be­lieve they have found their next big can­cer drug.

Ear­ly Mon­day the phar­ma gi­ant an­nounced that it was pay­ing Bel­gium’s ar­genx $500 mil­lion — $300 mil­lion as an up­front and $200 mil­lion for eq­ui­ty — to grab the world­wide com­mer­cial rights to cusat­uzum­ab (ARGX-110) to treat acute myeloid leukemia and high-risk myelodys­plas­tic syn­dromes. The deal al­so comes with $1.3 bil­lion in mile­stones.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.